Chronic exposure to melatonin receptor agonists does not alter their effects on suprachiasmatic nucleus neurons

European Journal of Pharmacology
S W YingE Mocaer

Abstract

Previous studies have demonstrated that melatonin and a novel melatonin receptor agonist, S20098 (N-[2-(7-methoxy-1-naphthyl) ethyl] acetamide), regulate neuronal firing activity of photically responsive cells in the suprachiasmatic nucleus in vivo. In the present study, we used several different methods to investigate the effects of chronic daily treatment with melatonin, S20098 (1.0 mg/kg, s.c.) or control vehicle for 14 d on responsiveness of suprachiasmatic nucleus cells to these agonists. Both chronic and acute application of drugs were carried out during the day-night transition period. We confirmed that suprachiasmatic nucleus cells from control animals were most sensitive at this circadian phase. Chronic drug treatments did not alter sensitivity of photically responsive suprachiasmatic nucleus cells to S20098 or melatonin given intraperitoneally (i.p.) or iontophoretically in vivo. Suprachiasmatic nucleus cells studied in brain slice preparations also responded similarly to micropressure ejections of melatonin receptor agonists regardless of drug pretreatment. These results indicate that chronic melatonin receptor agonist pretreatment does not result in desensitization of suprachiasmatic nucleus neuronal responses to th...Continue Reading

References

Apr 17, 1992·Journal of Medicinal Chemistry·S YousB Guardiola-Lemaitre
Nov 22, 1991·Brain Research·A J McArthurR A Prosser
Jan 3, 1990·European Journal of Pharmacology·D S Pickering, L P Niles
Mar 1, 1989·Endocrinology·J T LaitinenJ M Saavedra
Jan 1, 1986·Journal of Biological Rhythms·V M CassoneS M Armstrong
Oct 16, 1987·Neuroscience Letters·V M CassoneR Y Moore
Sep 1, 1993·Pharmacology, Biochemistry, and Behavior·S M ArmstrongJ R Redman
Dec 29, 1995·Cell·S M Reppert, D R Weaver
Jan 18, 1996·European Journal of Pharmacology·S W YingB Guardiola-Lemaitre
Jan 1, 1996·Behavioural Brain Research·R Y Moore
Jan 1, 1996·Behavioural Brain Research·A J LewyR L Sack
Jan 1, 1996·Behavioural Brain Research·M U Gillette, A J McArthur
Aug 1, 1996·Pharmacology, Biochemistry, and Behavior·L MartinetE Mocaer
Jan 16, 1997·The New England Journal of Medicine·A Brzezinski

❮ Previous
Next ❯

Citations

Mar 12, 2003·Life Sciences·Paula A Witt-EnderbyMelissa A Melan
Nov 18, 2006·Behavioural Pharmacology·Valérie Bertaina-AngladeElisabeth Mocaër
Nov 21, 2007·CNS Drugs·Seithikurippu R Pandi-PerumalDaniel P Cardinali
Sep 19, 2012·Progress in Retinal and Eye Research·Hai HuangXiong-Li Yang
Dec 2, 2015·Neurodegenerative Disease Management·Daniel J van WamelenNasir A Aziz
Apr 8, 2010·Human Psychopharmacology·Maria-Antonia Quera-SalvaChristian Guilleminault
May 12, 2004·Biochemical Pharmacology·Matthew J GerdinMargarita L Dubocovich
Apr 15, 2014·British Journal of Pharmacology·B Guardiola-LemaitreE Mocaër
Dec 17, 2008·Journal of Psychopharmacology·Y Le Strat, P Gorwood
Jun 26, 2010·Nature Reviews. Drug Discovery·Christian de BodinatMark J Millan
Mar 26, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mariusz PappElisabeth Mocaër
Dec 6, 2006·Expert Review of Neurotherapeutics·S R Pandi-PerumalM J Monti
Jan 30, 2018·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·F Sh ShagiakhmetovI Yu Shamakina
Aug 5, 2020·Pharmacological Reports : PR·Anna HaduchWładysława A Daniel
Apr 11, 2001·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·O Van ReethF W Turek

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.